Navigation Links
Hard to Treat Diseases (HTDS) Management Discussion
Date:10/1/2009

    Pink Sheets Filings Reply To Shareholders FAQ on Various Past News and
    General Corporate Update

SHENZHEN, China, Oct. 1 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) The issuer's China based operating subsidiary Mellow Hope and Serbia operating Subsidiary Slavica Bio Chem are providing news release to bring attention to today's Pink Sheets filing. The filing found on Pink Sheets HTDS listing or this link http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds

The company hopes that this filing bring its followers and shareholders up to date with various events and pending transactions, and to provide an update on past news releases. The filing is intensive 4 pages covering short sellers, naked short positions. The superficial "skull and bones" icon effecting HTDS, IP rights, cancer project and unsolicited buyer, H1N1 business and pending foreign defamation judgment and other FAQ topics of HTDS followers and shareholders.

The filing on Pink Sheets is timed to coincide and release at the same time as this news release shortly after 1:30pm EST.

To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR), 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A), Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Pennsylvania Breast Cancer Coalition Offers Seminar on Free Treatment for Breast Cancer
2. New approach for the treatment of malignant brain tumors
3. Treatment of severe burn injuries
4. Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half
5. Ulcerative colitis treatment reduces need for surgery by almost half
6. Cardiac stem cell trial seeks to treat some heart attack patients
7. Study Urges Treatment for Even Mild Gestational Diabetes
8. Chronic pain treatments work better together, says anesthesiologist
9. $16.8 million grant awarded to develop platelet recovery treatments
10. Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
11. Researchers develop an integrated treatment for veterans with chronic pain and posttraumatic stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 09, 2016 , ... Sir Grout, the leading hard surface ... announce that many of their franchises have received the Super Service Award from ... franchises received customer recognition through positive reviews and testimonials, as well as evaluations ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain Preservation Foundation’s (BPF) ... from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded by recent MIT ... of an intact rabbit brain for extremely long-term storage using a combination of ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates ... they are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, ... be enough to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... York, NY (PRWEB) , ... February 08, 2016 , ... ... are too much to handle, you are not alone. According to the Center for ... include heart disease, stroke, type 2 diabetes and certain types of cancer, some of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016 The global prefilled syringes market accounted ... expected to grow with a CAGR of 12.9% during ... segment dominated the global prefilled syringes market, with 90.1% ... --> The global market of prefilled syringes is ... geriatric population, increasing demand for vaccines, increasing prevalence of ...
(Date:2/9/2016)... 9, 2016 The life of Dr. Jan ... been anything but ordinary.  Twists of fate, combined with sheer ... and the constraints of communist Czechoslovakia to New ... go on to make history by playing a key role ... in the world, Remicade.  Dr. Vilcek brings readers along his ...
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Bluestar Silicones ... (LSR) product line for long-term implant applications and ... Medical Design & Manufacturing (MD&M) West Conference (Booth ... --> --> ... Silbione® Biomedical LSRs offer outstanding physical properties enabling ...
Breaking Medicine Technology: